Abstract: An HDR image sensor supporting LED Flicker Mitigation to reduce Motion Blur and a method of operating same are provided. A timing controller circuit generates at least one control signal that controls an operation of the image sensor. A split-photodiode (PD) pixel includes at least two or more photodiodes that may be independently exposed to one or more bursts of light from a light source. A first photodiode of the two or more photodiodes has a first exposure period that is longer in duration than a second exposure period of a second photodiode of the two or more photodiodes. The second photodiode performs a fragmented exposure operation in which a plurality of exposure periods of the second photodiode are shorter in duration than the first exposure period of the first photodiode, and include both continuous and fragmented exposure periods to capture the one or more bursts of light.

Abstract: An HDR image sensor supporting LED Flicker Mitigation to reduce Motion Blur and a method of operating same are provided. A timing controller circuit generates at least one control signal that controls an operation of the image sensor. A split-photodiode (PD) pixel includes at least two or more photodiodes that may be independently exposed to one or more bursts of light from a light source. A first photodiode of the two or more photodiodes has a first exposure period that is longer in duration than a second exposure period of a second photodiode of the two or more photodiodes. The second photodiode performs a fragmented exposure operation in which a plurality of exposure periods of the second photodiode are shorter in duration than the first exposure period of the first photodiode, and include both continuous and fragmented exposure periods to capture the one or more bursts of light.

Abstract: An HDR image sensor supporting LED Flicker Mitigation to reduce Motion Blur and a method of operating same are provided. A timing controller circuit generates at least one control signal that controls an operation of the image sensor. A split-photodiode (PD) pixel includes at least two or more photodiodes that may be independently exposed to one or more bursts of light from a light source. A first photodiode of the two or more photodiodes has a first exposure period that is longer in duration than a second exposure period of a second photodiode of the two or more photodiodes. The second photodiode performs a fragmented exposure operation in which a plurality of exposure periods of the second photodiode are shorter in duration than the first exposure period of the first photodiode, and include both continuous and fragmented exposure periods to capture the one or more bursts of light.

Abstract: A method for calculating disparity in a pair of images includes receiving a first image of a scene and designating the first image as a master image. A second image of the scene is received, and the second image is designated as a slave image. The master image is binarized to produce a binarized master image. The slave image is binarized to produce a binarized slave image. A matching cost associated with matching each pixel within the binarized master image with a corresponding set of candidate pixels within the binarized slave image is calculated. A probability density function is created based on the calculated matching costs associated with each pixel within the binarized master image. The created probability density function is used to produce a disparity for the master image and the slave image and to produce a confidence for the produced disparity.

Abstract: A method for calculating disparity in a pair of images includes receiving a first image of a scene and designating the first image as a master image. A second image of the scene is received, and the second image is designated as a slave image. The master image is binarized to produce a binarized master image. The slave image is binarized to produce a binarized slave image. A matching cost associated with matching each pixel within the binarized master image with a corresponding set of candidate pixels within the binarized slave image is calculated. A probability density function is created based on the calculated matching costs associated with each pixel within the binarized master image. The created probability density function is used to produce a disparity for the master image and the slave image and to produce a confidence for the produced disparity.

Abstract: A time of flight (ToF) sensor includes: a first pixel including a first photogate to receive light reflected by an object and generate a first phase signal, and a second photogate to generate a second phase signal having a phase difference of 180 degrees with respect to the first phase signal; a second pixel including a third photogate to receive the reflected light and generate a third phase signal different from the first phase signal and a fourth photogate to generate a fourth phase signal having a phase difference of 180 degrees with respect to the third phase signal; a first signal output unit to output the first and second phase signals; and a second signal output unit to output the third and fourth phase signals, wherein the first, second, third and fourth photogates output the first to fourth phase signals during a frame period.

Abstract: Methods for the treatment of spinal cord injury or traumatic brain injury are provided. In certain embodiments, the methods include the use of a molecular tweezers and/or nucleobase oligomer capable of inhibiting the accumulation or aggregation of one or more amyloidogenic proteins and/or synuclein proteins. Examples of treatments that may inhibit accumulation or aggregation of one or more amyloidogenic proteins and/or synuclein proteins include treatment with a synuclein antisense nucleobase oligomer or treatment with the molecular tweezers CLR01. These treatments may improve outcomes of spinal cord surgery or traumatic brain injury, including, without limitation, neuronal survival, neuronal regeneration, and recovery of neuronal functions.

Abstract: This invention provides novel compositions to inhibit the aggregation of amyloid proteins. In various embodiments the compositions comprise a molecular tweezers that binds lysine and/or arginine and thereby inhibits the aggregation of amyloidogenic proteins.

Abstract: The present invention relates to the field of protein misfolding diseases and thus to diseases which are associated with or induced by abnormal or pathogenic three-dimensional folding of proteins and/or peptides or which are linked to pathogenic conformational changes of proteins and/or peptides, such as Alzheimer's disease. Particularly, the present invention provides novel trimeric pyrazole compounds, which exhibit a therapeutic effectiveness in regard to the aforementioned protein misfolding diseases, and refers to their use for the treatment of such protein misfolding diseases, especially neurodegenerative diseases as well as to medicaments or pharmaceutical compositions comprising these compounds.

Abstract: The present invention relates to the field of protein misfolding diseases and thus to diseases which are associated with or induced by abnormal or pathogenic three-dimensional folding of proteins and/or peptides or which are linked to pathogenic conformational changes of proteins and/or peptides, such as Alzheimer's disease. Particularly, the present invention provides novel trimeric pyrazole compounds, which exhibit a therapeutic effectiveness in regard to the aforementioned protein misfolding diseases, and refers to their use for the treatment of such protein misfolding diseases, especially neurodegenerative diseases as well as to medicaments or pharmaceutical compositions comprising these compounds.

Abstract: This invention provides novel compositions to inhibit the aggregation of amyloid proteins. In various embodiments the compositions comprise a molecular tweezers that binds lysine and/or arginine and thereby inhibits the aggregation of amyloidogenic proteins.

Abstract: Novel backbone cyclized peptide analogs are formed by means of bridging groups attached via the alpha nitrogens of amino acid derivatives to provide novel non-peptidic linkages. Novel building units disclosed are N?(?-functionalized) amino acids constructed to include a spacer and a terminal functional group. One or more of these N?(?-functionalized) amino acids are incorporated into a peptide sequence, preferably during solid phase peptide synthesis. The reactive terminal functional groups are protected by specific protecting groups that can be selectively removed to effect either backbone-to-backbone or backbone-to-side chain cyclizations. The invention is specifically exemplified by backbone cyclized bradykinin antagonists having biological activity. Further embodiments of the invention are somatostatin analogs having one or two ring structures involving backbone cyclization.

Abstract: Novel backbone cyclized peptide analogs are formed by means of bridging groups attached via the alpha nitrogens of amino acid derivatives to provide novel non-peptidic linkages. Novel building units disclosed are N&agr;(&ohgr;-functionalized) amino acids constructed to include a spacer and a terminal functional group. One or more of these N&agr;(&ohgr;-functionalized) amino acids are incorporated into a peptide sequence, preferably during solid phase peptide synthesis. The reactive terminal functional groups are protected by specific protecting groups that can be selectively removed to effect either backbone-to-backbone or backbone-to-side chain cyclizations. The invention is specifically exemplified by backbone cyclized bradykinin antagonists having biological activity. Further embodiments of the invention are somatostatin analogs having one or two ring structures involving backbone cyclization.

Abstract: Novel backbone cyclized peptide analogs are formed by means of bridging groups attached via the alpha nitrogens of amino acid derivatives to provide novel non-peptidic linkages. Novel building units disclosed are N&agr;(&ohgr;-functionalized) amino acids constructed to include a spacer and a terminal functional group. One or more of these N&agr;(&ohgr;-functionalized) amino acids are incorporated into a peptide sequence, preferably during solid phase peptide synthesis. The reactive terminal functional groups are protected by specific protecting groups that can be selectively removed to effect either backbone-to-backbone or backbone-to-side chain cyclizations. The invention is specifically exemplified by backbone cyclized bradykinin antagonists having biological activity. Further embodiments of the invention are somatostatin analogs having one or two ring structures involving backbone cyclization.

Abstract: Novel backbone cyclized peptide analogs are formed by means of bridging groups attached via the alpha nitrogens of amino acid derivatives to provide novel non-peptidic linkages. Novel building units disclosed are N.sup..alpha. (.omega.-functionalized) amino acids constructed to include a spacer and a terminal functional group. One or more of these N.sup..alpha. (.omega.-functionalized) amino acids are incorporated into a peptide sequence, preferably during solid phase peptide synthesis. The reactive terminal functional groups are protected by specific protecting groups that can be selectively removed to effect either backbone-to-backbone or backbone-to-side chain cyclizations. The invention is exemplified by backbone cyclized bradykinin antagonists having biological activity. Further embodiments of the invention are somatostatin analogs having one or two ring structures involving backbone cyclization.

Abstract: Novel backbone cyclized peptide analogs are formed by means of bridging groups attached via the alpha nitrogens of amino acid derivatives to provide novel non-peptidic linkages. Novel building units disclosed are N.sup..alpha. (.omega.-functionalized)amino acids constructed to include a spacer and a terminal functional group. One or more of these N.sup..alpha. (.omega.-functionalized) amino acids are incorporated into a peptide sequence, preferably during solid phase peptide synthesis. The reactive terminal functional groups are protected by specific protecting groups that can be selectively removed to effect either backbone-to-backbone or backbone-to-side chain cyclizations. The invention is exemplified by backbone cyclized bradykinin antagonists having biological activity. Further embodiments of the invention are somatostatin analogs having one or two ring structures involving backbone cyclization.

Abstract: Novel backbone cyclized peptide analogs are formed by means of bridging groups attached via the alpha nitrogens of amino acid derivatives to provide novel non-peptidic linkages. Novel building units disclosed are N.sup..alpha. (.omega.-functionalized) amino acids constructed to include a spacer and a terminal functional group. One or more of these N.sup..alpha. (.omega.-functionalized) amino acids are incorporated into a peptide sequence, preferably during solid phase peptide synthesis. The reactive terminal functional groups are protected by specific protecting groups that can be selectively removed to effect either backbone-to-backbone or backbone-to-side chain cyclizations. The invention is exemplified by backbone cyclized bradykinin antagonists having biological activity. Further embodiments of the invention are somatostatin analogs having one or two ring structures involving backbone cyclization.